VERICEL CORPORATION Common Stock, Value, Issued
VERICEL CORPORATION (VCEL) had Common Stock, Value, Issued of $750.80 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:CommonStockValue · last filed 2026-07-30
- 2026-06-30: Common Stock, Value, Issued $750.80M.
- 2026-03-31: Common Stock, Value, Issued $739.00M.
- 2025-12-31: Common Stock, Value, Issued $730.66M.
- 2025-09-30: Common Stock, Value, Issued $721.14M.
| Period end | Common Stock, Value, Issued |
|---|---|
| 2026-06-30 | $750.80M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $739.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $730.66M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $721.14M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $711.24M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $699.41M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $684.78M 10-K · filed 2026-02-26 |
| 2024-09-30 | $669.74M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $654.97M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $641.18M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $629.23M 10-K · filed 2025-02-27 |
| 2023-09-30 | $621.01M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $612.06M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $602.10M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $593.25M 10-K · filed 2024-02-29 |
| 2022-09-30 | $584.90M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $575.01M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $563.48M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $553.90M 10-K · filed 2023-02-23 |
| 2021-09-30 | $544.62M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $534.00M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $519.36M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $510.06M 10-K · filed 2022-02-24 |
| 2020-09-30 | $502.59M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $499.10M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $493.77M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $489.75M 10-K · filed 2021-02-24 |
| 2019-09-30 | $485.14M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $480.05M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $474.81M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $471.18M 10-K · filed 2020-02-25 |
| 2018-09-30 | $468.45M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $463.48M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $389.07M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $383.02M 10-K · filed 2019-02-26 |
| 2017-09-30 | $377.71M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $369.54M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $368.68M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $329.72M 10-K · filed 2018-03-05 |
| 2016-09-30 | $310.21M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $309.44M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $308.51M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $307.77M 10-K · filed 2017-03-13 |
| 2015-09-30 | $307.21M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $306.63M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $305.93M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $305.01M 10-K · filed 2016-03-14 |
| 2014-09-30 | $304.78M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $262.79M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $259.14M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $253.27M 10-K · filed 2015-03-25 |
| 2013-09-30 | $251.36M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $245.98M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $245.55M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $243.22M 10-K · filed 2014-03-13 |
| 2012-09-30 | $242.77M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $239.45M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $229.87M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $228.88M 10-K · filed 2013-03-18 |
| 2011-09-30 | $227.90M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $226.97M 10-Q · filed 2011-08-15 |
| 2010-12-31 | $225.10M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |